--- title: "MannKind Co. (NASDAQ:MNKD) Shares Acquired by 180 Wealth Advisors LLC" description: "180 Wealth Advisors LLC increased its stake in MannKind Co. (NASDAQ:MNKD) by 12.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm now owns " type: "news" locale: "en" url: "https://longbridge.com/en/news/207544538.md" published_at: "2024-06-28T15:49:08.000Z" --- # MannKind Co. (NASDAQ:MNKD) Shares Acquired by 180 Wealth Advisors LLC > 180 Wealth Advisors LLC increased its stake in MannKind Co. (NASDAQ:MNKD) by 12.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm now owns 1,942,210 shares of the biopharmaceutical company's stock, making it their 6th biggest holding. MannKind's stock is currently valued at $5.21. 180 Wealth Advisors LLC increased its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 12.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,942,210 shares of the biopharmaceutical company's stock after purchasing an additional 216,880 shares during the quarter. MannKind comprises about 1.6% of 180 Wealth Advisors LLC's portfolio, making the stock its 6th biggest holding. 180 Wealth Advisors LLC owned 0.72% of MannKind worth $8,798,000 as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Parkman Healthcare Partners LLC lifted its holdings in MannKind by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 2,498,624 shares of the biopharmaceutical company's stock valued at $9,095,000 after acquiring an additional 429,677 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in MannKind by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,066,844 shares of the biopharmaceutical company's stock valued at $7,523,000 after acquiring an additional 30,433 shares during the last quarter. Invesco Ltd. lifted its holdings in MannKind by 1.6% in the 3rd quarter. Invesco Ltd. now owns 1,621,765 shares of the biopharmaceutical company's stock valued at $6,698,000 after acquiring an additional 25,319 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in MannKind by 10.1% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 973,200 shares of the biopharmaceutical company's stock worth $4,019,000 after buying an additional 89,005 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in MannKind by 77.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 740,078 shares of the biopharmaceutical company's stock worth $3,057,000 after buying an additional 322,791 shares during the period. 49.55% of the stock is owned by institutional investors and hedge funds. ## Insider Buying and Selling In related news, EVP David Thomson sold 23,537 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $4.66, for a total value of $109,682.42. Following the transaction, the executive vice president now owns 873,616 shares in the company, valued at $4,071,050.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.00% of the stock is currently owned by corporate insiders. ## Analysts Set New Price Targets MNKD has been the topic of several recent analyst reports. Rodman & Renshaw initiated coverage on MannKind in a report on Thursday, June 13th. They set a "buy" rating and a $8.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $6.50 price objective on shares of MannKind in a report on Thursday, May 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $8.00. **Check Out Our Latest Analysis on MNKD** ## MannKind Stock Down 1.5 % Shares of MNKD traded down $0.08 during trading hours on Friday, reaching $5.21. The company's stock had a trading volume of 373,131 shares, compared to its average volume of 2,719,187. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 176.39 and a beta of 1.27. MannKind Co. has a 1-year low of $3.17 and a 1-year high of $5.75. The company has a 50 day moving average of $4.61 and a two-hundred day moving average of $4.17. MannKind (NASDAQ:MNKD - Get Free Report) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.02. The company had revenue of $66.26 million for the quarter, compared to the consensus estimate of $60.55 million. MannKind had a negative return on equity of 3.35% and a net margin of 3.78%. The firm's quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) EPS. As a group, analysts forecast that MannKind Co. will post 0.1 EPS for the current fiscal year. ## MannKind Profile (Free Report) MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. ## Further Reading - Five stocks we like better than MannKind - Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed - Salesforce Stock: Meeting Recap, AI Focus, and Forecast - Breakout Stocks: What They Are and How to Identify Them - Is CAVA Overextended? A Closer Look at This High-Flying Stock - Consumer Staples Stocks, Explained - Nike Stock Falls to Bargain Basement After Analysts Slash Targets **Want to see what other hedge funds are holding MNKD?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MannKind Co. (NASDAQ:MNKD - Free Report). *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* → Where AI is REALLY Going Next (From InvestorPlace) (Ad)## Should you invest $1,000 in MannKind right now? Before you consider MannKind, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list. While MannKind currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [MNKD.US - Mannkind](https://longbridge.com/en/quote/MNKD.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 曼恩凯德（MNKD）估值检查：随着 Afrezza 儿童里程碑的达成，无针胰岛素的机会正在开启 | MannKind (MNKD) 已在 INHALE-1ST Afrezza 研究中招募了首位儿童患者，这可能导致首款无针胰岛素的问世。该公司的股价在过去 30 天内上涨了 8.64%，在过去 90 天内上涨了 13.20%，当前价格为 5. | [Link](https://longbridge.com/en/news/276150484.md) | | 曼恩凯德生物医疗（MNKD）将于周三公布财报 | MannKind (NASDAQ:MNKD) 将于 2 月 25 日发布 2025 年第四季度财报，分析师预测每股亏损 0.01 美元。该股开盘价为 5.54 美元，市值为 17 亿美元。最近的分析师评级包括 Zacks 将其评级下调至 “ | [Link](https://longbridge.com/en/news/276206881.md) | | FDA 正在审查 Afrezza 吸入胰岛素是否可以用于儿童和青少年 | 美国食品药品监督管理局（FDA）已接受 MannKind Corporation 提交的 Afrezza 吸入粉末的补充生物制剂许可申请（sBLA），该药物适用于 1 型或 2 型糖尿病的儿童和青少年，预计将在 2026 年 5 月 29 | [Link](https://longbridge.com/en/news/275305828.md) | | 2026 年 FDA 对 Afrezza 和 FUROSCIX 在曼恩凯德生物医疗（MNKD）的决策如何改变了其投资故事 | MannKind Corporation 已概述了关键的监管里程碑，包括预计在 2026 年对 Afrezza 和 FUROSCIX 的 FDA 决策。审查时间表的一致性可能会影响投资者对 MannKind 产品组合和收入潜力的看法。FDA | [Link](https://longbridge.com/en/news/272157412.md) | | 斯图尔特·A·特罗斯，首席人力与工作场所官员，报告出售曼恩凯德生物医疗公司的普通股 | 曼恩凯德生物医疗的首席人事与工作场所官 Stuart A. Tross 已报告出售该公司的普通股。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供信息参考，不应被视为财务或法律建议。曼恩凯德生物医疗对 2026 年 1 月 9 | [Link](https://longbridge.com/en/news/272136429.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.